Gilead Sciences, Inc DEFA14A, filed Mar 30, 2021

Gilead Sciences, Inc. (GILD)

DEFA14A 2021-03-30

Added on October 22, 2026

CHECK THE APPROPRIATE BOX:
☐		Preliminary Proxy Statement
☐		Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐		Definitive Proxy Statement
☑		Definitive Additional Materials
☐		Soliciting Material Under Rule 14a-12

PAYMENT OF FILING FEE (CHECK THE APPROPRIATE BOX):
☑	No fee required.
☐	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
		1) Title of each class of securities to which transaction applies:
		2) Aggregate number of securities to which transaction applies:
		3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
		4) Proposed maximum aggregate value of transaction:
		5) Total fee paid:
☐	Fee paid previously with preliminary materials:
☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
		1) Amount previously paid:
		2) Form, Schedule or Registration Statement No.:
		3) Filing Party:
		4) Date Filed:

		Board
Voting Items		Recommends
1.	To elect the nine director nominees named in the Proxy Statement to serve for the next year and until their successors are elected and qualified.
	Nominees:
1a.	Jacqueline K. Barton, Ph.D.		For
1b.	Jeffrey A. Bluestone, Ph.D.		For
1c.	Sandra J. Horning, M.D.		For
1d.	Kelly A. Kramer		For
1e.	Kevin E. Lofton		For
1f.	Harish Manwani		For
1g.	Daniel P. O’Day		For
1h.	Javier J. Rodriguez		For
1i.	Anthony Welters		For
2.	To ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of Gilead for the fiscal year ending December 31, 2021.		For
3.	To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.		For
4.	To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairperson of the Board of Directors be an independent director.		Against


GILEAD SCIENCES, INC. ATTN: INVESTOR RELATIONS 333 LAKESIDE DRIVE FOSTER CITY, CA 94404		Your Vote Counts! GILEAD SCIENCES, INC. 2021 Annual Meeting Vote by May 11, 2021 11:59 PM ET




D42713-P48614

			For complete information and to vote, visit www.ProxyVote.com
			Control #

Smartphone users Point your camera here and vote without entering a control number		Vote Virtually at the Meeting* May 12, 2021 10:00 a.m. Pacific Time

	Virtually at: www.virtualshareholdermeeting.com/GILD2021